CENTANY Drug Patent Profile

When do Centany patents expire, and when can generic versions of Centany launch?

Centany is a drug marketed by Padagis Us and is included in one NDA.

The generic ingredient in CENTANY is mupirocin. There are sixteen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the mupirocin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Centany

A generic version of CENTANY was approved as mupirocin by PADAGIS ISRAEL on November 7^th, 2003.

Summary for CENTANY

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	85
Clinical Trials:	2
Patent Applications:	7,767
What excipients (inactive ingredients) are in CENTANY?	CENTANY excipients list
DailyMed Link:	CENTANY at DailyMed

Recent Clinical Trials for CENTANY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cook Children's Medical Center	Phase 2
University of Texas Southwestern Medical Center	Phase 2
National Jewish Health	Phase 2

See all CENTANY clinical trials

US Patents and Regulatory Information for CENTANY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Padagis Us	CENTANY	mupirocin	OINTMENT;TOPICAL	050788-001	Dec 4, 2002		DISCN	No	No

Expired US Patents for CENTANY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Padagis Us	CENTANY	mupirocin	OINTMENT;TOPICAL	050788-001	Dec 4, 2002

International Patents for CENTANY

See the table below for patents covering CENTANY around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0933081	Compositions pharmaceutiques contenant mupirocine (Pharmaceutical compositions containing mupirocin)
Israel	123143	PHARMACEUTICAL COMPOSITIONS CONTAINING MUPIROCIN
Spain	2165723
Germany	69900561

CENTANY Market Analysis and Financial Projection

Last updated: April 26, 2026

CENTANY (monotherapy topical antibiotic) — Market Dynamics and Financial Trajectory

What is CENTANY and where does it play in the market?

CENTANY is a prescription topical antibiotic product line using mupirocin (pseudomonad-free formulation; topical use for bacterial skin infections). It sits in the topical antibiotics segment, competing with other topical antimicrobials used in conditions such as localized bacterial skin infections and wound-related infections where topical treatment is clinically appropriate.

The market dynamics for CENTANY are driven by three factors:

• Antibiotic stewardship pressure reduces broad and repetitive topical antibiotic use, tightening prescribing patterns.
• Formulation and access economics matter because topical antibiotics are typically evaluated on total course cost, local formulary status, and ease-of-use.
• Tender and payer positioning (hospital procurement and pharmacy benefit design) dominate volumes where reimbursement is restrictive.

How do regulatory status and access shape demand?

Demand is typically constrained or accelerated by:

• Formulary placement and reimbursement: topical antibiotic adoption tracks payer rules and local clinical guidelines.
• Product switching behavior: when multiple topical antibiotics are available, prescribers switch based on availability, price, and perceived tolerability rather than novelty.
• Safety and resistance narratives: regulators and payers increasingly push clinicians toward shorter durations and narrower-use criteria, compressing peak usage.

For business forecasting, the main takeaway is that CENTANY’s revenue path is unlikely to resemble systemic blockbuster trajectories. It is more consistent with a specialty topical portfolio pattern: moderate sales growth when access improves, then plateau once formularies mature.

---

What market forces determine sales momentum for topical antibiotics?

Which demand drivers matter most?

Topical antibiotic market share is influenced by:

• Guideline interpretation for local bacterial infections and wound care protocols.
• Healthcare provider behavior under stewardship frameworks.
• Channel structure: hospital purchasing vs retail uptake changes how fast volume scales.

What supply and competitive pressures exist?

Key competitive forces in topical antibiotics include:

• Generic substitution risk: if equivalent mupirocin presentations are available at lower prices, originator-like pricing erodes.
• Line extensions and alternative actives: competitive products with better tolerability, vehicle performance, or dosing convenience can displace.
• Availability risk: supply continuity affects volume, especially in hospital tenders.

How sensitive is the category to price and reimbursement?

Topical antibiotics are highly price sensitive because payers often treat them as therapeutic equivalents within restricted clinical windows. When a payer can manage cost by preferring lower-priced options, growth depends on:

• protected reimbursement status,
• contract pricing,
• and clinical differentiation that holds up under payer scrutiny.

---

What does the financial trajectory usually look like for CENTANY?

A credible financial trajectory for CENTANY follows the mechanics of a topical antibiotic:

1. Launch or re-entry phase: growth driven by formulary wins and early prescriber uptake.
2. Maturation: expansion stabilizes once guidelines and reimbursement lock in usage patterns.
3. Erosion or consolidation: price pressure and generic alternatives reduce margins and can cap volume unless the product sustains differentiated access.

From a financial modeling standpoint, the trajectory depends less on pipeline-led hype and more on:

• net price trends (discounting and tender dynamics),
• reimbursed share within target indications,
• and durability of exclusive or privileged access.

---

How should investors and R&D teams frame CENTANY economics?

What are the cost and margin levers?

For topical antibiotics, financial performance usually hinges on:

• Net price vs list price (tender discounts and pharmacy channel rebates),
• COGS stability tied to raw materials and fill-finish scale,
• marketing intensity vs incremental access (less about brand pull, more about formulary execution).

If CENTANY holds premium access, it sustains higher net pricing. If payer behavior shifts toward lowest-cost equivalents, revenue growth slows and margins compress.

What business risks affect revenue volatility?

Revenue volatility is typically driven by:

• tender cycles and contract resets,
• supply disruptions,
• and shifts in stewardship rules that reduce prescribing frequency or duration.

---

What are the actionable business dynamics to track next for CENTANY?

What KPIs determine whether the trajectory improves or worsens?

Track:

• Formulary wins and renewals by geography and channel (hospital vs retail).
• Share of prescriptions within mupirocin/topical antibiotic classes (where data is available).
• Net price trend including tender contracting and rebate changes.
• Volume per treated episode (duration and dosing frequency), which often changes under stewardship.

Where is upside realistically sourced?

Upside tends to come from:

• improved payer coverage under narrow clinical criteria,
• enhanced patient convenience that supports adherence,
• and procurement wins that expand hospital utilization.

Where is downside most likely?

Downside tends to come from:

• stronger generic substitution,
• restrictive payer edits that narrow reimbursed indications,
• and increased tender-driven discounting that reduces net realizations.

---

Market trajectory snapshot

Because CENTANY’s market behavior is category-driven rather than pipeline-driven, the most reliable trajectory signals come from access and pricing rather than clinical trial tailwinds.

Dimension	What to expect for CENTANY	What changes the path
Growth profile	Moderate, access-led	New formulary and procurement wins
Margin structure	Sensitive to net price	Tender discounts and rebate revisions
Volume driver	Treated episodes under guideline rules	Stewardship changes and payer restrictions
Competitive pressure	High from generics and alternates	Switching to lower-cost equivalents

---

Key Takeaways

• CENTANY operates in the topical antibiotic segment where access, reimbursement, and stewardship dictate volumes more than brand scale.
• The financial trajectory is typically maturation-led: growth occurs when formularies and procurement routes improve; it then plateaus and can erode under tender discounting and generic substitution.
• The highest-leverage KPIs for predicting the next revenue inflection are net price trend, reimbursed share, and prescribing duration rules.

---

FAQs

1. Is CENTANY likely to behave like a blockbuster?
   No. Topical antibiotic sales typically follow an access-and-pricing curve shaped by reimbursement and stewardship rather than blockbuster-style demand elasticity.

2. What is the biggest financial risk for CENTANY?
   Net price compression driven by tender contracting and substitution to lower-priced equivalents.

3. What metrics best predict near-term sales?
   Formulary coverage and renewal status, procurement wins, net price trend, and prescribing duration.

4. How do stewardship policies affect growth?
   They can reduce treated episode frequency or shorten duration, which lowers volume even if formulary access remains stable.

5. Where can CENTANY find upside?
   In new access routes: hospital tenders, favorable reimbursement edits, and differentiated formulation performance that holds under payer scrutiny.

---

References

[1] Bloomberg. Drug market coverage and pricing analytics platform (accessed via internal database).